StockData
Bioxytran, Inc logo

Bioxytran, Inc (BIXT) stock

BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30
$0.02−0.00 (-3.95%)

Close on Oct 19, 2026Market cap $2.56MP/E –Yield –

Bioxytran gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Bioxytran's gross profit for the twelve months ending Jun 30, 2018 was $83.76K, down 25.6% year over year. For fiscal 2017 it was $87.10K, down 42.0% from the year before. The highest annual figure on record is $219.95K in fiscal 2013.

Annual gross profit

PeriodPeriod endValueChange
FY2017Dec 31, 2017$87.10K-42.0%
FY2016Dec 31, 2016$150.19K+25.0%
FY2015Dec 31, 2015$120.14K+9.6%
FY2014Dec 31, 2014$109.64K-50.2%
FY2013Dec 31, 2013$219.95K+15.2%
FY2012Dec 31, 2012$190.98K+233.8%
FY2011Dec 31, 2011$57.22K+373.0%
FY2010Dec 31, 2010$12.10K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2018Jun 30, 2018$12.20K-39.3%
Q1 FY2018Mar 31, 2018-$1.93K–
Q4 FY2017Dec 31, 2017-$6.60K-118.5%
Q3 FY2017Sep 30, 2017$80.09K+27.2%
Q2 FY2017Jun 30, 2017$20.08K–
Q1 FY2017Mar 31, 2017-$6.24K–
Q4 FY2016Dec 31, 2016$35.73K–
Q3 FY2016Sep 30, 2016$62.94K–

More Bioxytran figures

See a number that looks wrong?